A Phase I Dose-Escalation Clinical Trial of Bronchoscopic Cryoimmunotherapy in Advanced-Stage NSCLC

Introduction: Outcomes for NSCLC remain suboptimal. Recent data suggest that cryoablation can generate antitumor immune effects. In this first-in-human phase I clinical trial, we investigated the safety and feasibility of bronchoscopic cryoimmunotherapy (BCI) delivered during standard-of-care bronch...

Full description

Bibliographic Details

Published in:	JTO Clinical and Research Reports
Main Authors:	Jun-Chieh J. Tsay, MD, MS, Antonio Velez, MD, Destiny Collazo, BS, Isaac Laniado, MD, Jamie Bessich, MD, Vivek Murthy, MD, Andrew DeMaio, MD, Samaan Rafeq, MD, Benjamin Kwok, MD, Fares Darawshy, MD, Ray Pillai, MD, Kendrew Wong, MD, Yonghua Li, MD, PhD, Rosemary Schluger, RN, Alena Lukovnikova, BS, Sofia Roldan, BS, Matt Blaisdell, BS, Fernanda Paz, Kelsey Krolikowski, BS, Katherine Gershner, MD, Yong Liu, PhD, Judy Gong, BA, Sara Borghi, PhD, Fang Zhou, MD, Aristotelis Tsirigos, PhD, Harvey Pass, MD, Leopoldo N. Segal, MD, MS, Daniel H. Sterman, MD
Format:	Article
Language:	English
Published:	Elsevier 2025-08-01
Subjects:	Bronchoscopic cryoimmunotherapy Immunotherapy Tumor microenvironment NSCLC Phase I trial
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364325000669